Snapshot from May 30, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / Atara Biotherapeutics Faces...
Regulatory class action lawsuit

Atara Biotherapeutics Faces Securities Lawsuit

Analysis based on 6 articles · First reported May 01, 2026 · Last updated May 14, 2026

Sentiment
-50
Attention
4
Articles
6
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The class action lawsuit against Atara Biotherapeutics is expected to negatively impact its stock price and investor confidence due to allegations of securities fraud and misleading statements. This event highlights the regulatory risks associated with biotechnology companies and their drug development processes.

Biotechnology Legal Services
Event Summary

The The Schall Law Firm has initiated a class action lawsuit against Atara Biotherapeutics, alleging violations of securities laws. The lawsuit claims that Atara Biotherapeutics made false and misleading statements to investors between May 20, 2024, and January 9, 2026. Specifically, the complaint states that Atara Biotherapeutics suffered from manufacturing problems and deficiencies in its ALLELE study, making it unlikely that the United States — Food and Drug Administration would approve its Biologics License Application (BLA) for tabelecleucel. The company is accused of overstating the prospects of tabelecleucel and facing a higher risk of regulatory action due to its manufacturing issues. Investors who purchased Atara Biotherapeutics' securities during the specified period and suffered losses are encouraged to join the lawsuit.

Key Actions
100 The Schall Law Firm filed class action lawsuit Atara Biotherapeutics
90 Atara Biotherapeutics made misleading statements
Entities Involved
stock
Atara Biotherapeutics
Atara Biotherapeutics is the defendant in a class action lawsuit for allegedly making false and misleading statements regarding its manufacturing processes and the prospects of its drug tabelecleucel, leading to investor losses.
Importance 100 Sentiment -70
priv
The Schall Law Firm
The The Schall Law Firm is representing investors in a class action lawsuit against Atara Biotherapeutics, alleging securities fraud.
Importance 80 Sentiment 50
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration's potential non-approval of Atara Biotherapeutics' BLA for tabelecleucel due to manufacturing problems and study deficiencies is a key point in the lawsuit.
Importance 30 Sentiment 0
govactor
United States — United States Securities and Exchange Commission
The United States — United States Securities and Exchange Commission's rules (Rule 10b-5) and sections of the Securities Exchange Act of 1934 are cited in the class action lawsuit against Atara Biotherapeutics.
Importance 20 Sentiment 0
per
Brian Schall
Brian Schall is associated with The The Schall Law Firm and is encouraging investors to contact the firm regarding the class action lawsuit.
Importance 10 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.